Clinical trials of TB vaccines: Harmonization and cooperation

被引:0
|
作者
Mahomed, Hassan [1 ]
Fourie, P. Bernard [2 ]
机构
[1] Univ Cape Town, S African TB Vaccine Initiat, Inst Infect Dis & Mol Med, Fac Hlth Sci, ZA-7925 Cape Town, South Africa
[2] Univ Pretoria, Fac Hlth Sci, Dept Med Microbiol, ZA-0002 Pretoria, South Africa
基金
英国惠康基金;
关键词
Tuberculosis; Vaccines; Clinical trials; Clinical endpoints; Routes of administration; CANDIDATE MALARIA VACCINE; TUBERCULOSIS VACCINES; IMMUNIZATION; SAFETY; BCG;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A new efficacious tuberculosis (TB) vaccine has the potential to dramatically assist control efforts for the global TB epidemic. Good progress has been made with the clinical development of new TB vaccine candidates with twelve being actively tested in clinical trials. However, there are many challenges that need to be addressed before a new vaccine is licensed for public use. The diversity of risk in populations needs to be factored into clinical development plans, specific but feasible clinical endpoints need to be agreed upon, and TB vaccines need to be effective in both uninfected and infected populations. An achievable efficacy target needs to be set while standardisation of trial outcomes and critical choices based on the vaccine development pipeline need to be made. Alternative routes of vaccine administration should be thoroughly explored, sufficient adequately prepared trial sites for performing TB vaccine assessments are required and creative use of study designs should be used to expedite progress towards licensure while at the same time containing costs. Lastly, there needs to be sufficient funding to support TB vaccine development. These challenges can be met through commitment by all role-players within the TB vaccine arena and with support from external stakeholders. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:S21 / S24
页数:4
相关论文
共 50 条
  • [1] Real world TB vaccines: clinical trials in TB-endemic regions
    Doherty, TM
    [J]. VACCINE, 2005, 23 (17-18) : 2109 - 2114
  • [2] Clinical studies of TB vaccines
    Hawkridge, Anthony
    [J]. HUMAN VACCINES, 2009, 5 (11): : 773 - 776
  • [3] TB vaccines in clinical development
    Ginsberg, Ann M.
    Ruhwald, Morten
    Mearns, Helen
    McShane, Helen
    [J]. TUBERCULOSIS, 2016, 99 : S16 - S20
  • [4] Cooperation in Clinical Trials
    Wood, William C.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2011, 212 (04) : 431 - 439
  • [5] Ensuring Standardization and Harmonization in Multicenter Clinical Trials
    Christian, Paul E.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2009, 50 (06) : 20N - 20N
  • [6] Advancing TB vaccines to phase I clinical trials in the US: regulatory/manufacturing/licensing issues
    Rowland, SS
    Mayner, RL
    Barker, L
    [J]. TUBERCULOSIS, 2005, 85 (1-2) : 39 - 46
  • [7] Tuberculosis vaccines in clinical trials
    Rowland, Rosalind
    McShane, Helen
    [J]. EXPERT REVIEW OF VACCINES, 2011, 10 (05) : 645 - 658
  • [8] Clinical trials of HIV vaccines
    Graham, BS
    [J]. ANNUAL REVIEW OF MEDICINE, 2002, 53 : 207 - 221
  • [9] Papillomavirus vaccines in clinical trials
    Galloway, DA
    [J]. LANCET INFECTIOUS DISEASES, 2003, 3 (08): : 469 - 475
  • [10] Harmonization and streamlining of research oversight for pragmatic clinical trials
    O'Rourke, P. Pearl
    Carrithers, Judith
    Patrick-Lake, Bray
    Rice, Todd W.
    Corsmo, Jeremy
    Hart, Raffaella
    Drezner, Marc K.
    Lantos, John D.
    [J]. CLINICAL TRIALS, 2015, 12 (05) : 449 - 456